Phase 3 Lung Cancer Trial, Recruiting NCT05717803 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT05717803
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a consent form and complete the study as planned
  • People aged between 18 and 80 years old
  • People with a general health and activity level rated as fully active or with only minor limitations (this is measured using a standard scale called ECOG — confirm with trial site)
  • People who have not had lung cancer surgery before
  • People confirmed to have a specific type of lung cancer called invasive lung adenocarcinoma, identified either during or after surgery
  • People whose lung nodule appears mostly as "ground glass" on imaging (a hazy, cloud-like appearance rather than a solid mass)
  • People whose nodule has a solid-to-total size ratio between 0 and 0.5, and a total tumour size between 2 and 3 centimetres
  • People whose cancer has not spread to nearby lymph nodes or to other parts of the body
  • People whose tumour a surgeon has assessed as being able to be fully removed
  • People who have not received chemotherapy or radiotherapy before

Who may not be able to join:

  • People whose nodule does not fall within the required size range (2–3 cm) or solid-to-total ratio (0–0.5)
  • People whose tumour a surgeon has assessed as unable to be fully removed
  • People whose lung cancer type has not been confirmed as adenocarcinoma through cell or tissue testing
  • People who have previously had lung cancer surgery
  • People who have previously received radiotherapy or chemotherapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Haiquan Chen, M.D., Fudan University

Phone: +86-13122677592

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
15 February 2023
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

5-year disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov